Phaseline

Targets › HTR5A

HTR5A (5-hydroxytryptamine receptor 5A): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Other.

G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen. Also functions as a receptor for ergot alkaloid derivatives and other psychoactive substances. (UniProt, P47898)

Open in Phaseline: the race on HTR5A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, Basel, SwitzerlandDMT
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–
University Hospital, Basel, SwitzerlandLSD
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–

Conditions

Healthy (2)

Modalities

small molecule (2)

Companies

University Hospital, Basel, Switzerland (2)

Related targets

HTR1A (2) HTR1B (2) HTR1D (2) HTR7 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.